Catalog No.
FHK28414
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
PerCP
Applications
FCM
Target
IGPR-1, CD28H, CD28 homolog, Immunoglobulin and proline-rich receptor 1, TMIGD2, IGPR1, Transmembrane and immunoglobulin domain-containing protein 2
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q96BF3
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0319
Note
For research use only.
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein., PMID:25549724
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2., PMID:25869386
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis., PMID:26071192
The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account., PMID:27191544
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3., PMID:28258693
The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma., PMID:31089395
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy., PMID:31108883
B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling., PMID:32005952
Iron Deprivation in Human T Cells Induces Nonproliferating Accessory Helper Cells., PMID:32284314
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1., PMID:33229411
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target., PMID:34244312
HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells., PMID:35175496
Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma., PMID:35226778
Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy., PMID:35439678
NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells., PMID:35585985
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy., PMID:35933091
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model., PMID:36386885
Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer., PMID:36982953
HHLA2 immune-regulatory roles in cancer., PMID:37011487
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies., PMID:37069229
B7-H7: A potential target for cancer immunotherapy., PMID:37290327
TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells., PMID:38167704
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer., PMID:38522775
Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaque., PMID:38707998
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors., PMID:38718110
The Importance of HHLA2 in Solid Tumors-A Review of the Literature., PMID:38786018
Human endogenous retrovirus-H long terminal repeat-associating 2: an emerging immune checkpoint for cancer immunotherapy., PMID:38973642
For research use only. Not for human or drug use.
